Evaluating the efficacy of different doses of tocilizumab in treating critically ill COVID-19 patients: a single-center retrospective cohort study.

ABSTRACT:

Objectives

To evaluate the therapeutic efficacy of different doses of tocilizumab (TCZ) in patients with severe or critical COVID-19.

Methods

In this single-center retrospective cohort study conducted from January 2023 to January 2024, 56 hospitalized patients with severe or critical COVID-19 who received TCZ were included. Patients were categorized into three groups based on the number of TCZ doses administered: one dose (n = 16), two doses (n = 32), and three doses (n = 8). The primary outcomes were in-hospital mortality and 30-day mortality following the first dose. Secondary outcomes included changes in inflammatory marker levels, length of hospital stay, duration of mechanical ventilation, and incidence of complications during hospitalization.

Results

After adjus

SUBMITTER: Gao J 

PROVIDER: S-EPMC12328359 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature